University of the Sunshine Coast
Welcome,         Profile    Billing    Logout  
 11 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scott, Robert M
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
ITV2002, NCT05604690: Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers

Completed
1
40
RoW
Avacc 10, Outer Membrane Vesicles (OMV) : OMV alone in vehicle, Placebo
Intravacc B.V., Novotech (Australia) Pty Limited
COVID-19
08/23
01/24
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Active, not recruiting
N/A
525
US
Investigational LUX-Dx ICM Implant
Boston Scientific Corporation
Heart Failure
05/26
06/26
Harrison, Michael R
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
TRIO CAP, NCT05017935: RADIANCE Continued Access Protocol

Active, not recruiting
N/A
300
US
Renal Denervation
ReCor Medical, Inc.
Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
12/28
12/28
Patel, Chirag
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05305365: Study Assessing QBS72S for Treating Brain Metastases

Recruiting
2
40
US
QBS72S, QBS10072S
Melanie Hayden Gephart, Quadriga Biosciences, Inc.
Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease, LMD
02/25
08/26
Shue, Hong
NCT04674683 / 2019-002521-30: Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Active, not recruiting
3
450
Europe, Japan, US, RoW
HBI-8000 in combination with nivolumab, For HBI-8000: tudicdinostat; For nivolumab: OPDIVO®, Placebo in combination with nivolumab, For nivolumab: OPDIVO®
HUYABIO International, LLC., Bristol-Myers Squibb
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
12/24
10/25
KEYNOTE-C14, NCT04986852: Olinvacimab With Pembrolizumab in Patients With mTNBC

Recruiting
2
30
RoW
Olinvacimab, Pembrolizumab
PharmAbcine, Merck Sharp & Dohme LLC
Metastatic Triple-Negative Breast Cancer
02/25
08/26
ON-5001, NCT06022029: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cemiplimab in Patients with Advanced Solid Tumors and Lymphomas.

Recruiting
1
168
US, RoW
ONM-501, Cemiplimab, Libtayo
OncoNano Medicine, Inc.
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
04/26
08/26
Shavaksha, Sorab
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT04735575: A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Recruiting
1/2
66
RoW
EMB-06
Shanghai EpimAb Biotherapeutics Co., Ltd.
Relapsed or Refractory Multiple Myeloma
12/23
03/25
Bechaz, Nicole
No trials found

Download Options